[68Ga]Pentixafor (15 MBq, intravenous injection, single dose) is suitable for PET imaging in the PC-3 prostate cancer xenograft model[2].
[18F]AlF-NOTA-Pentixather (0.30 MBq, intravenous injection, single dose) can target the CXCR4 receptor for specific PET imaging in the Daudi lymphoma xenograft SCID mouse model[4].
| Animal Model: | PC-3 prostate cancer xenograft (nude mouse) model[2] |
| Dosage: | 15 MBq (Pentixafor labeled with 68Gallium (68Ga), [68Ga]Pentixafor) |
| Administration: | Intravenous injection (i.v., injection via tail vein), single dose |
| Result: | Resulted in moderate contrast in PET imaging performed in the PC-3 tumor model. |
| Animal Model: | Daudi lymphoma xenograft (SCID mouse) model[4] |
| Dosage: | 0.30 MBq ([18F]AlF-NOTA-Pentixather, approx. 195 pmol/0.251 μg) |
| Administration: | Intravenous injection (i.v.), single dose, imaging performed at 60 minutes post-injection |
| Result: | Exhibited CXCR4-specific tumor accumulation, with low uptake in background organs. |
